Clinical Trial Update: Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update indicates that BAH243, a lentiviral vector gene therapy, is being investigated for sickle cell disease in Phase 1/Phase 2 and is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Crisis
• Sickle Cell Disease

Drugs mentioned

• BAH243 (Lentiviral vector BAH243)

Snippet

Sponsor: Essen Biotech | Conditions: Sickle Cell Disease, Sickle-Cell Disease With Crisis | Phase 1, Phase 2 | Status: RECRUITING